Friday, April 26, 2024, Washington, DC, 12:15 PM – 1:45 PM Eastern Time

What I Tell My Patients: Integrating New Research Information into Current Clinical Care

A Complimentary NCPD Hybrid Symposium Series Held During the 49th Annual ONS Congress

Non-Small Cell Lung Cancer with an EGFR Mutation

 
Location
Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Program Schedule — Eastern Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — NCPD Lunch Meeting

Meeting Room
Independence Ballroom (Meeting Level 4)

This event will also be webcast live.
Please see Registration tab for details.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.  
 
Faculty
Marianne J Davies, DNP, ACNP, AOCNP, FAAN
Program Manager, Care Signature
Oncology Service Line, Yale New Haven Health
Oncology Nurse Practitioner-Senior APP II
Yale Cancer Center
Smilow Cancer Hospital at Yale New Haven
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

Alexander I Spira, MD, PhD
CEO and Clinical Director, NEXT Virginia
Director, Virginia Cancer
Specialists Research Program
Fairfax, Virginia


Jillian Thompson, MSN, ANP-BC, AOCNP
Nurse Practitioner
MedStar Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Washington, DC

Helena Yu, MD
Medical Oncologist
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24-28, 2024 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Eastern Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — NCPD Lunch Meeting

What I Tell My Patients About ...

The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC)

  • Spectrum of EGFR mutations found in NSCLC; clinical relevance of and similarities and differences among various detectable EGFR mutations
  • Incidence of targetable EGFR mutations in localized and metastatic disease; optimal timing of EGFR testing
  • Available platforms to identify EGFR mutations in patients with NSCLC; advantages and limitations of next-generation sequencing versus one-off testing
  • Reliability of plasma-based assays to document the presence of actionable EGFR mutations; current clinical utility
  • Role of repeat biomarker testing in the care of patients with progressive NSCLC with an EGFR mutation

The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation

  • Long-term findings, including overall survival outcomes, with adjuvant osimertinib for Stage IB to Stage IIIA NSCLC with an EGFR mutation after complete tumor resection
  • Protection against central nervous system (CNS) disease recurrence observed with adjuvant osimertinib
  • Patient selection for and appropriate incorporation into practice of adjuvant osimertinib
  • Choosing between osimertinib and immune checkpoint inhibition for patients eligible for both treatments
  • Tolerability of osimertinib in the adjuvant setting; appropriate threshold for dose reduction, dose delays or treatment discontinuation for patients with NSCLC receiving adjuvant osimertinib
  • Ongoing efforts seeking to further define the role of osimertinib in the management of nonmetastatic NSCLC with an EGFR mutation

Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation

  • Long-term benefit observed with up-front osimertinib monotherapy for patients with metastatic NSCLC with an EGFR mutation
  • Intracranial response rates and rates of CNS progression documented with up-front osimertinib
  • Sequencing of osimertinib relative to local therapies, such as stereotactic radiosurgery and whole-brain radiation therapy, for patients with NSCLC with an EGFR mutation and brain metastases
  • Utility of rechallenge with osimertinib for patients who receive the drug in the adjuvant setting and experience subsequent disease progression
  • Strategies to prevent and/or ameliorate osimertinib-related gastrointestinal, dermatologic and other adverse events (AEs)

Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation

  • Rationale for the evaluation of osimertinib in combination with chemotherapy as first-line treatment for patients with NSCLC with an EGFR mutation
  • Progression-free survival (PFS) and other key efficacy and safety outcomes observed with first-line osimertinib/chemotherapy compared to osimertinib alone
  • Recent FDA approval of first-line osimertinib/chemotherapy and selection of optimal candidates for this strategy
  • Mechanistic similarities and differences between the bispecific antibody amivantamab and EGFR tyrosine kinase inhibitors (TKIs); rationale for the selection of lazertinib as a therapeutic partner for amivantamab in clinical trials
  • PFS and other efficacy outcomes observed with first-line amivantamab in combination with lazertinib compared to osimertinib for patients with NSCLC and an EGFR mutation
  • Potential clinical role of first-line amivantamab/lazertinib

Common Toxicities Associated with Amivantamab

  • Spectrum, frequency and severity of common toxicities with amivantamab, such as dermatologic AEs, fatigue, musculoskeletal pain and stomatitis
  • Incidence and timing of infusion-related reactions with amivantamab; appropriate premedication and infusion modification strategies
  • Pathophysiology of ocular toxicities associated with amivantamab, such as keratitis, dry eye, conjunctival redness, blurred vision and uveitis; importance of consultation with ophthalmology for patients experiencing symptoms
  • Other, less frequently occurring side effects with amivantamab, such as interstitial lung disease (ILD)/pneumonitis; recommended approaches for monitoring and management
  • Effect on the tolerability of amivantamab when administered in combination with other systemic therapies, such as lazertinib and/or chemotherapy

The Current and Future Management of Progressive NSCLC with an EGFR Mutation

  • Published findings with and ongoing evaluation of osimertinib combined with other agents, such as savolitinib and tepotinib, to overcome common mechanisms of resistance
  • Recently presented data with amivantamab in combination with chemotherapy with and without lazertinib for patients with NSCLC with an EGFR mutation who experience disease progression on osimertinib
  • Rationale for targeting HER3 in patients with NSCLC with an EGFR mutation; structural components and mechanism of action of patritumab deruxtecan (HER3-DXd)
  • Published efficacy and safety findings with HER3-DXd for NSCLC with an EGFR mutation after progression on EGFR TKI therapy and platinum-based chemotherapy
  • Potential clinical roles of amivantamab/chemotherapy, with or without lazertinib, and HER3-DXd for progressive NSCLC with an EGFR mutation

Tolerability and Other Practical Considerations with HER3-DXd

  • Frequency of dose interruptions, dose reductions and treatment discontinuation with HER3-DXd in published clinical trials
  • Rates of Grade ≥3 cytopenias reported among patients receiving HER3-DXd; optimal monitoring of complete blood counts
  • Other commonly reported treatment-related AEs observed with HER3-DXd, such as gastrointestinal issues and fatigue
  • Incidence and severity of ILD reported with HER3-DXd; appropriate monitoring and management

Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations

  • Rationale for the lack of activity of traditional EGFR TKIs in this patient subset; biological basis for the activity of amivantamab
  • Long-term efficacy and safety data with amivantamab for patients with metastatic NSCLC and EGFR exon 20 insertion mutations who experience disease progression on or after platinum-based chemotherapy
  • Key findings with the combination of amivantamab and platinum-based chemotherapy for newly diagnosed advanced NSCLC with EGFR exon 20 insertion mutations
  • Recent FDA approval of amivantamab in combination with chemotherapy as first-line treatment for NSCLC with EGFR exon 20 insertion mutations; implications for therapeutic sequencing
  • Rationale for the recent voluntary withdrawal of mobocertinib for NSCLC with EGFR exon 20 insertion mutations

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Acknowledge published and emerging clinical trial findings with EGFR tyrosine kinase inhibitors (TKIs) for localized and locally advanced NSCLC with an EGFR mutation, and identify patients for whom this novel approach would be warranted.
  • Evaluate the documented efficacy of chemotherapy with EGFR TKI therapy, and consider the current role of this strategy as first-line treatment for metastatic NSCLC and an EGFR mutation.
  • Appreciate the biological rationale for dual inhibition of MET and EGFR for NSCLC with an EGFR mutation, and understand data establishing the benefit of this approach in the front-line and relapsed/refractory settings.
  • Consider the rationale for targeting HER3 in NSCLC with an EGFR mutation, and review the structural components of and available research with novel HER3-directed antibody-drug conjugates.
  • Understand the biology of EGFR exon 20 insertion mutations, and evaluate how available therapies should be used for patients with these abnormalities.
  • Recognize common side effects associated with available and emerging agents with activity in NSCLC with an EGFR mutation, and develop supportive management strategies to minimize and/or ameliorate these toxicities.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Davies — No relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr SpiraAdvisory Committees: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Gritstone bio, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, ADC Therapeutics, AI Therapeutics, Alkermes, Amgen Inc, Arch Therapeutics Inc, ArriVent Biopharma, Astellas, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, BluPrint Oncology, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo Inc, Gritstone bio, Ignyta Inc, Incyte Corporation, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MacroGenics Inc, Medikine, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Nalo Therapeutics, Novartis, Plexxikon Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Roche Laboratories Inc, Rubius Therapeutics, Scorpion Therapeutics, Synthekine, Takeda Pharmaceuticals USA Inc. Ms ThompsonAdvisory Committees: Janssen Biotech Inc, Mirati Therapeutics Inc; Nonrelevant Financial Relationship: Targeted Oncology. Dr YuConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc; Research Funding to My Institution: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Novartis, Pfizer Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence Ballroom (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2024 ONS Congress and is connected to the Walter E Washington Convention Center by an underground concourse.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ONS Congress.

IN-PERSON Registration for nurses and other healthcare providers

I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.